CA
NZ
UK
AU
IND
US
MBX Biosciences, Inc. (NASDAQ: MBX) announced earnings per share (EPS) of $-0.78 for the quarter ending June 30, 2026, falling short of consensus expectations. While the result highlights ongoing financial pressures, the company continues to advance its clinical pipeline, positioning it for future growth …
Moderna's recent FDA approval for its COVID-19 vaccine represents a important achievement in regulatory support for the company. However, despite this win, market reactions have been tepid, with investors expressing hesitance about the durability of positive momentum. The approval underscores the vaccine's safety and …
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced a second-quarter loss of $-0.43, which falls short of the consensus estimate of $-0.39, raising caution among investors. The company revealed these financial results on August 6, 2026, alongside updates on its ongoing clinical trials. The reported …
Immunocore Holdings plc (NASDAQ: IMCR) posted second‑quarter net product revenue of $115.9 million, an 18% increase from $98.0 million a year earlier, while the loss for the period narrowed dramatically to $0.8 million, translating to a $‑0.02 earnings per share versus the $0.01 consensus …
Immunovant, Inc. has announced a net loss of $153.2 million for the fiscal first quarter ending June 30, 2026. This translates to a loss per share of $0.75, which is larger compared to the $0.71 loss reported in the same quarter last year. The …
This surge comes against a comparative anchor as Insmed reported an EPS of $-0.76 in the previous quarter, outperforming the consensus estimate of $-0.98. The dramatic revenue growth highlights the company’s operational success, especially as it navigates a competitive environment marked by live performances …
Intellia Therapeutics, Inc. (NASDAQ: NTLA) reported a second quarter EPS of $-0.80, slightly better than the consensus estimate of $-0.82. The company's performance reflects a determined approach in the gene-editing space, positioning itself for future growth. The results come amid fluctuations in share performance, …
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has reported exceptional quarterly results, achieving record revenues of around $99.3 million for the second quarter ending June 30, 2026. This revenue represents a significant 66% increase compared to approximately $60 million during the same period last year, as …
The company reported revenue of $113 million for the quarter ending June 30, which marks a significant increase from $85.2 million in the same period last year. However, the earnings per share (EPS) of $0.31 fell short of the $0.36 consensus estimate, which could …
The new trading environment will start on August 7, marking a key moment for the stock, which faces notable downward pressure this year.
Please wait processing your request...